

Olmesartan Provides Multi-level CV Protection in Hypertensive Individuals.

Mandraffino G, et al. *PLoS One*. 2017; 12(3): e0173030.

- CD34+ circulating progenitor cells (CD34+CPCs) are multipotent cells which can delay development of atherosclerosis and cardiovascular disease in hypertensive individuals.
- After 6 months of olmesartan (20 mg/day) treatment, significant decreases were noted for BP, inflammatory markers (CRP and fibrinogen), oxidative stress, and left ventricular mass, while the CD34+CPC cell number increased.

In addition to its expected pharmacological effects, olmesartan provides multilevel CV protection in hypertensive individuals.